2,142
Views
1
CrossRef citations to date
0
Altmetric
Articles

Validation and application of a simple and rapid stability-indicating liquid chromatographic assay for the quantification of caffeine from human saliva

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon

References

  • Eichenwald, E. C.; Watterberg, K. L.; Aucott, S.; Benitz, W. E.; Cummings, J. J.; Goldsmith, J.; Poindexter, B. B.; Puopolo, K.; Stewart, D. L.; Wang, K. S. Apnea of Prematurity. Pediatrics 2016, 137, 1–7. DOI: 10.1542/peds.2015-3757.
  • Dukhovny, D.; Lorch, S. A.; Schmidt, B.; Doyle, L. W.; Kok, J. H.; Roberts, R. S.; Kamholz, K. L.; Wang, N.; Mao, W.; Zupancic, J. A. F. Economic Evaluation of Caffeine for Apnea of Prematurity. Pediatrics 2011, 127, e146–e155. DOI: 10.1542/peds.2010-1014.
  • Oliphant, E. A.; McKinlay, C. J. D.; McNamara, D. G.; Alsweiler, J. M. Caffeine Prophylaxis to Improve Intermittent Hypoxaemia in Infants Born Late Preterm: A Randomised Controlled Dosage Trial (Latte Dosage Trial). BMJ Open 2020, 10, e038271. DOI: 10.1136/bmjopen-2020-038271.
  • Gorodischer, R.; Burtin, P.; Hwang, P.; Levine, M.; Koren, G. Saliva versus Blood Sampling for Therapeutic Drug Monitoring in Children: Patient and Parental Preferences and an Economic Analysis. Ther. Drug Monit. 1994, 16, 437–536. DOI: 10.1097/00007691-199410000-00001.
  • Horning, M. G.; Brown, L.; Nowlin, J.; Lertratanangkoon, K.; Kellaway, P.; Zion, T. E. Use of Saliva in Therapeutic Drug Monitoring. Clin. Chem. 1977, 23, 157–164. DOI: 10.1093/clinchem/23.2.157.
  • Dobson, N. R.; Liu, X.; Rhein, L. M.; Darnall, R. A.; Corwin, M. J.; McEntire, B. L.; Ward, R. M.; James, L. P.; Sherwin, C. M. T.; Heeren, T. C.; et al. Salivary Caffeine Concentrations Are Comparable to Plasma Concentrations in Preterm Infants Receiving Extended Caffeine Therapy. Br. J. Clin. Pharmacol. 2016, 82, 754–761. DOI: 10.1111/bcp.13001.
  • Alkaysi, H. N.; Salem, M. S.; El-Sayed, Y. M. High Performance Liquid Chromatographic Analysis of Caffeine Concentrations in Plasma and Saliva. J. Clin. Pharm. Ther. 1988, 13, 109–110. DOI: 10.1111/j.1365-2710.1988.tb00165.x.
  • Carrillo, J. A.; Christensen, M.; Ramos, S. I.; Alm, C.; Dahl, M. L.; Benítez, J.; Bertilsson, L. Evaluation of Caffeine as an In Vivo Probe for CYP1A2 Using Measurements in Plasma, Saliva, and Urine. Ther. Drug Monit. 2000, 22, 409–417. DOI: 10.1097/00007691-200008000-00008.
  • Perera, V.; Gross, A. S.; McLachlan, A. J. Caffeine and Paraxanthine HPLC Assay for CYP1A2 Phenotype Assessment Using Saliva and Plasma. Biomed. Chromatogr. 2010, 24, 1136–1144. DOI: 10.1002/bmc.1419.
  • Newton, R.; Broughton, L. J.; Lind, M. J.; Morrison, P. J.; Rogers, H. J.; Bradbrook, I. D. Plasma and Salivary Pharmacokinetics of Caffeine in Man. Eur. J. Clin. Pharmacol. 1981, 21, 45–52. DOI: 10.1007/BF00609587.
  • Jordan, N. Y.; Mimpen, J. Y.; van den Bogaard, W. J. M.; Flesch, F. M.; van de Meent, M. H. M.; Torano, J. S. Analysis of Caffeine and Paraxanthine in Human Saliva with Ultra-High-Performance Liquid Chromatography for CYP1A2 Phenotyping. J. Chromatogr. B 2015, 995–996, 70–73. DOI: 10.1016/j.jchromb.2015.05.020.
  • McDowall, R. D.; Doyle, E.; Murkitt, G. S.; Picot, V. S. Sample Preparation for the HPLC Analysis of Drugs in Biological Fluids. J. Pharm. Biomed. Anal. 1989, 7, 1087–1096. DOI: 10.1016/0731-7085(89)80047-0.
  • US Food and Drug Administration; U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM). Bioanalytical Method Validation: Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration: Silver Spring, MD, 2018.
  • Dong, Y.; Speer, C. P. Late-Onset Neonatal Sepsis: Recent Developments. Arch. Dis. Child Fetal Neonatal Ed. 2015, 100, F257–F263. DOI: 10.1136/archdischild-2014-306213.
  • Council of Europe. European Pharmacopoeia (Ph. Eur.), 10th ed.; Council of Europe: Strasbourg, 2019.
  • New Zealand Ministry of Health. Communicable Disease Control Manual | Ministry of Health NZ; New Zealand Ministry of Health: Wellington, 2012.
  • Li, W.; Jian, W.; Fu, Y. Basic Sample Preparation Techniques in LC‐MS Bioanalysis. In Sample Preparation in LC‐MS Bioanalysis; Wiley: Hoboken, NJ, 2019; pp 1–30. DOI: 10.1002/9781119274315.ch1.
  • Bogialli, S.; Corcia, A.; Di; Nazzari, M. Extraction Procedures. In Food Toxicants Analysis; Elsevier: Amstadam, The Netherlands, 2007; pp 269–297. DOI: 10.1016/B978-044452843-8/50010-9.
  • Polson, C.; Sarkar, P.; Incledon, B.; Raguvaran, V.; Grant, R. Optimization of Protein Precipitation Based upon Effectiveness of Protein Removal and Ionization Effect in Liquid Chromatography-Tandem Mass Spectrometry. J. Chromatogr. B 2003, 785, 263–275. DOI: 10.1016/S1570-0232(02)00914-5.
  • Berlin, C. M.; Denson, M. H.; Daniel, C. H.; Ward, R. M. Disposition of Dietary Caffeine in Milk, Saliva, and Plasma of Lactating Women. Pediatrics 1984, 73, 59–63. DOI: 10.1542/peds.73.1.59.
  • Chaabane, A.; Chioukh, F. Z.; Chadli, Z.; Ben Fredj, N.; Ben Ameur, K.; Ben Hmida, H.; Boughattas, N. A.; Monastiri, K.; Aouam, K. Therapeutic Drug Monitoring of Caffeine in Preterm Infants: Could Saliva Be an Alternative to Serum? Therapie 2017, 72, 685–689. DOI: 10.1016/j.therap.2017.06.004.
  • Barnes, A. R.; Hebron, B. S.; Smith, J. Stability of Caffeine Oral Formulations for Neonatal Use. J. Clin. Pharm. Ther. 1994, 19, 391–396. DOI: 10.1111/j.1365-2710.1994.tb00699.x.
  • Mehta, A. C. Practice Research: Strategies for Stability Studies on Hospital Pharmaceutical Preparations. Int. J. Pharm. Pract. 2011, 2, 49–52. DOI: 10.1111/j.2042-7174.1993.tb00720.x.
  • Sigma-Aldrich. Caffeine Solution (C6035)–Datasheet. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/195/539/c6035-slbj7833vdat.pdf (accessed Jun 17, 2022).